R Češka

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 895 citations · Full text

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom, Tomas Hala, Michael A. Bolognese et al. · New England Journal of Medicine · 2014 · 700 citations · Full text

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 658 citations

Cardiovascular Disease, Pcsk9 Inhibitor Evolocumab, Pharmacology +9

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet et al. · European Heart Journal · 2015 · 530 citations · Full text

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

Steven E. Nissen, Erik S.G. Stroes, Ricardo E. Dent‐Acosta et al. · JAMA · 2016 · 502 citations · Full text